A Multicenter, Open-label, Non-randomized Phase I/IIa Clinical Trial to Evaluate INR102 Injection in Patients With Prostate Cancer

计划入组 55 人 · 首次发布于 2025 年 5 月 14 日

A Study of PET/CT Imaging Using INR101 Injection in Healthy Male Subjects and Patients With Suspected Prostate Cancer

计划入组 32 人 · 首次发布于 2024 年 6 月 25 日

TRC102 and Temozolomide for Relapsed Solid Tumors and Lymphomas

计划入组 93 人 · 首次发布于 2013 年 5 月 10 日

BNC105

C₂₀H₂₁O₁₀P

IMX102

UNC1062

Liminatus Pharma to Acquire InnocsAI in $320 Million Deal, Gaining Next-Generation CAR-T Pipeline for Hematologic and Solid Tumors

GlycoNex Partners with Sterling for GNX102-ADC Clinical Trial Production

GlycoNex Partners with Sterling for GNX102-ADC Clinical Trial Manufacturing